Ginsenoside Rg1

Ginsenoside Rg1 at a Glance

Ginsenoside Rg1 is the major protopanaxatriol-type saponin of Asian ginseng and one of its marquee “active” molecules — conventionally pitched as the stimulating counterpart to Rb1’s calming profile.

Its laboratory reputation rests on neurotrophic and pro-cognitive signals and nitric-oxide-mediated vasodilation.

As with the other ginsenosides, poor absorption and extensive gut-bacterial transformation stand between the in-vitro record and any human claim.

Rg1 vs. Rb1: Ginseng’s Two Opposing Saponins

Ginseng’s two headline saponins are not variations on a theme. They sit on opposite sides of a single biosynthetic branch point, they end up as different metabolites, and in at least one well-characterised system they do opposite things.

The chemistry is one hydroxyl group. Both are dammarane triterpene glycosides, but Rb1 is built on protopanaxadiol (PPD) — sugars at C-3 and C-20 — while Rg1 is built on protopanaxatriol (PPT), which carries an extra hydroxyl at C-6 and hangs its sugars at C-6 and C-20. In the plant, PPT is made from PPD by a single cytochrome P450, CYP716A53v2 ^{18Reference 18Han JY et al. · 2012Cytochrome P450 CYP716A53v2 catalyzes the formation of protopanaxatriol from protopanaxadiol during ginsenoside biosynthesis in Panax ginsengView study →}. Ginseng root carries around 43 ginsenosides in all, sorted into the PPD group (Rb1, Rb2, Rc, Rd), the PPT group (Re, Rf, Rg1) and the odd oleanane-type Ro ^{23Reference 23So SH et al. · 2018ReviewRed ginseng monograph — reviewView study →}.

	Ginsenoside Rg1	Ginsenoside Rb1
Aglycone class	Protopanaxatriol (PPT)	Protopanaxadiol (PPD)
Sugars	Glucose at C-6 and C-20	Two glucoses at C-3, two at C-20
Richer in	Panax ginseng (Asian)	Panax quinquefolius (American)
Gut end-product	Rh1 → F1 → protopanaxatriol	Rd → F2 → compound K
Angiogenesis	Promotes (eNOS, PI3K/Akt)	Inhibits (PEDF via ERβ)
CNS reputation	Stimulating	Calming
Cholinergic effect	Inhibits acetylcholinesterase	No effect on AChE

The angiogenesis split is the sharpest evidence that the two are not interchangeable. A 2004 Circulation study set out to explain why ginseng extract is reported both to heal wounds and to suppress tumours, and found the answer in the Rg1:Rb1 ratio: mass-spectrometric fingerprinting of American, Chinese, Korean and Sanqi ginseng showed the ratio varies by species and origin, and Matrigel implants reconstituted at different ratios behaved accordingly — Rg1 dominance produced angiogenesis, Rb1 the opposite ^{15Reference 15Sengupta S et al. · 2004In vitroModulating angiogenesis: the yin and the yang in ginseng — in vivo and in vitroView study →}. Rg1 promoted neovascularisation of an implanted polymer scaffold and drove endothelial proliferation, chemoinvasion and tube formation through nitric-oxide synthase and PI3K→Akt; Rb1 blocked the earliest step, endothelial chemoinvasion ^{15Reference 15Sengupta S et al. · 2004In vitroModulating angiogenesis: the yin and the yang in ginseng — in vivo and in vitroView study →}, acting through pigment epithelium-derived factor via the oestrogen-β receptor ^{16Reference 16Chen CF et al. · 2008ReviewComparison of the pharmacological effects of Panax ginseng and Panax quinquefolium — reviewView study →}.

The pharmacological contrast extends past the vasculature, though less starkly. A head-to-head comparison in scopolamine-impaired mice found both saponins improved memory, but by different routes: Rg1 was the stronger on water-maze acquisition and inhibited acetylcholinesterase, which Rb1 did not touch; Rb1 was the more effective at restoring hippocampal serotonin ^{17Reference 17Wang Q et al. · 2010AnimalComparison of ginsenosides Rg1 and Rb1 for their effects on improving scopolamine-induced learning and memory impairment in mice — animal modelView study →}. The older species-level reading — P. ginseng as the “hot”, stimulating ginseng because it is Rg1-rich, American ginseng as the calming one because it is Rb1-rich — comes from the same asymmetry, and is better treated as a chemotype generalisation than a property of either molecule ^{21Reference 21Wan JB et al. · 2006Chemical characteristics for different parts of Panax notoginseng using pressurized liquid extraction and HPLC-ELSDView study →}.

One caution runs the other way. The two saponins share a poor-absorption problem, and both are substantially transformed by gut bacteria before anything reaches the blood — but they are transformed into different molecules. Rb1’s route ends at compound K, which has its own pharmacology and its own early human trials. Rg1 does not produce compound K; it is deglycosylated toward Rh1 and F1 and on to the protopanaxatriol aglycone ^{12,25Reference 12Hasegawa H · 2004ReviewProof of the mysterious efficacy of ginseng: metabolic activation of ginsenoside — deglycosylation by intestinal bacteria and esterification with fatty acid — reviewView study →Reference 25Odani T et al. · 1983AnimalStudies on the absorption, distribution, excretion and metabolism of ginseng saponinsView study →}. Evidence about compound K therefore says nothing about oral Rg1.

What It's Used For

Ginsenoside Rg1 is the leading protopanaxatriol (PPT)-type saponin of Asian ginseng and, alongside its sibling ginsenoside Rb1, one of the two molecules most often credited with ginseng’s activity. Where Rb1 (a protopanaxadiol saponin) leans CNS-depressant, Rg1 is the reputed CNS-stimulating, “adaptogenic” counterweight — and the Rg1:Rb1 ratio is the classic chemical discriminator between Panax ginseng (higher Rg1) and P. quinquefolius/American ginseng (higher Rb1) ^{8Reference 8Xu QF et al. · 2003AnimalPharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats — animal modelView study →}.

Its most-cited laboratory signals are neurotrophic / pro-cognitive effects, nitric-oxide-mediated vasodilation and angiogenesis (via a non-genomic glucocorticoid-receptor action), plus anti-fatigue and a distinct estrogen-like activity ^{2,3,4,5,9Reference 2Li F et al. · 2016AnimalGinsenoside Rg1 ameliorates hippocampal long-term potentiation and memory in an Alzheimer’s disease model — animal modelView study →Reference 3Leung KW et al. · 2006In vitroSignaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells — in vitroView study →Reference 4Leung KW et al. · 2006In vitroGinsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related PI3-kinase/Akt and β-catenin/T-cell factor-dependent pathway in human endothelial cells — in vitroView study →Reference 5Lei C et al. · 2023AnimalGinsenoside Rg1 can reverse fatigue behavior in CFS rats by regulating EGFR and affecting taurine and mannose 6-phosphate metabolism — animal modelView study →Reference 9Gao QG et al. · 2019In vitroGinsenoside Rg1 activates ligand-independent estrogenic effects via rapid estrogen receptor signaling pathway — in vitroView study →}.

The overriding caveat is that all of this is preclinical, and Rg1 is poorly absorbed and rapidly metabolized, so isolated-Rg1 effects have never been demonstrated in a human trial.

Evidence by IndicationStrength of support · Beta

01Neuroprotection & cognitionShaky38%Isolated Rg1 in multiple rodent aging/AD models + a preclinical systematic review; no human data ^{1,2,10Reference 1Zhu J et al. · 2014AnimalGinsenoside Rg1 prevents cognitive impairment and hippocampus senescence in a rat model of D-galactose-induced aging — animal modelView study →Reference 2Li F et al. · 2016AnimalGinsenoside Rg1 ameliorates hippocampal long-term potentiation and memory in an Alzheimer’s disease model — animal modelView study →Reference 10Liang HY et al. · 2021Systematic reviewPreclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease — systematic review of animal studiesView study →}

02Vascular — NO & angiogenesisShaky30%Isolated Rg1, endothelial-cell + rodent studies; mechanism well-mapped, no human data ^{3,4Reference 3Leung KW et al. · 2006In vitroSignaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells — in vitroView study →Reference 4Leung KW et al. · 2006In vitroGinsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related PI3-kinase/Akt and β-catenin/T-cell factor-dependent pathway in human endothelial cells — in vitroView study →}

03Anti-fatigue / adaptogenicShaky18%Isolated Rg1 in fatigue/aerobic-capacity rodent models; small and mechanistic ^{5Reference 5Lei C et al. · 2023AnimalGinsenoside Rg1 can reverse fatigue behavior in CFS rats by regulating EGFR and affecting taurine and mannose 6-phosphate metabolism — animal modelView study →}

04Estrogenic activityShaky15%Isolated Rg1 in vitro (ER-dependent); negative in the in-vivo uterotrophic test ^{6,7Reference 6Chan RY et al. · 2002In vitroEstrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng — in vitroView study →Reference 7Chen WF et al. · 2012In vitroEstrogenic effects of ginsenoside Rg1 in endometrial cells in vitro were not observed in immature CD-1 mice or ovariectomised mice model — in vitro and animal modelView study →}

Mechanisms

Pharmacokinetics

Poor oral bioavailability is the load-bearing fact. As a large, tri-glycosylated PPT saponin, Rg1 crosses the gut wall badly: measured oral bioavailability sits at the low end — around 18% in one rat model and reported across studies from roughly 2% up to ~20% of dose, with the bulk (≈40%) recovered unabsorbed in feces ^{8Reference 8Xu QF et al. · 2003AnimalPharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats — animal modelView study →}. What is absorbed is cleared quickly and distributed/excreted with substantial biliary and urinary loss ^{11Reference 11Feng L et al. · 2010AnimalPharmacokinetics, tissue distribution, metabolism, and excretion of ginsenoside Rg1 in rats — animal modelView study →}. Critically, Rg1 is deglycosylated by intestinal bacteria — sugars are stripped stepwise (Rg1 → Rh1 → F1, onward toward the protopanaxatriol aglycone) — so much of the “active” exposure is actually to these secondary metabolites, which are more absorbable and often more potent than Rg1 itself ^{12,13Reference 12Hasegawa H · 2004ReviewProof of the mysterious efficacy of ginseng: metabolic activation of ginsenoside — deglycosylation by intestinal bacteria and esterification with fatty acid — reviewView study →Reference 13Sun Y et al. · 2022ReviewNew therapeutic approaches to and mechanisms of ginsenoside Rg1 against neurological diseases — reviewView study →}. Rat work from 1983 established the point for both headline saponins at once, tracking the decomposition of Rg1 and Rb1 through the digestive tract and finding neither survives it intact ^{25Reference 25Odani T et al. · 1983AnimalStudies on the absorption, distribution, excretion and metabolism of ginseng saponinsView study →}. The two routes are separate: the PPD saponin Rb1 funnels down to compound K, Rg1 does not ^{12Reference 12Hasegawa H · 2004ReviewProof of the mysterious efficacy of ginseng: metabolic activation of ginsenoside — deglycosylation by intestinal bacteria and esterification with fatty acid — reviewView study →}. The practical consequence: dosing intact Rg1 orally delivers little parent molecule to tissue, and the pharmacology seen in cell studies is not what an oral dose achieves in a person.

Clinical Trials

There are essentially no registered trials of isolated ginsenoside Rg1 — all human ginseng data are at the whole-extract level, so any benefit cannot be attributed to Rg1 specifically. The isolated-molecule literature is entirely preclinical.

Last checked: September 2026.

Isolate vs. Plant Studies

Every Rg1 result above is an isolate result, and none of them is human. That is an unusual combination. The isolated molecule has been studied hard — in rodent aging and Alzheimer’s models ^{1,2,10Reference 1Zhu J et al. · 2014AnimalGinsenoside Rg1 prevents cognitive impairment and hippocampus senescence in a rat model of D-galactose-induced aging — animal modelView study →Reference 2Li F et al. · 2016AnimalGinsenoside Rg1 ameliorates hippocampal long-term potentiation and memory in an Alzheimer’s disease model — animal modelView study →Reference 10Liang HY et al. · 2021Systematic reviewPreclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease — systematic review of animal studiesView study →}, in endothelial cells and Matrigel implants ^{3,4,15Reference 3Leung KW et al. · 2006In vitroSignaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells — in vitroView study →Reference 4Leung KW et al. · 2006In vitroGinsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related PI3-kinase/Akt and β-catenin/T-cell factor-dependent pathway in human endothelial cells — in vitroView study →Reference 15Sengupta S et al. · 2004In vitroModulating angiogenesis: the yin and the yang in ginseng — in vivo and in vitroView study →}, in fatigue models ^{5Reference 5Lei C et al. · 2023AnimalGinsenoside Rg1 can reverse fatigue behavior in CFS rats by regulating EGFR and affecting taurine and mannose 6-phosphate metabolism — animal modelView study →} and in estrogen-receptor assays ^{6,9Reference 6Chan RY et al. · 2002In vitroEstrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng — in vitroView study →Reference 9Gao QG et al. · 2019In vitroGinsenoside Rg1 activates ligand-independent estrogenic effects via rapid estrogen receptor signaling pathway — in vitroView study →} — while the human ginseng literature is entirely at the level of standardised whole-root extract, where Rg1 is one of forty-odd saponins ^{23Reference 23So SH et al. · 2018ReviewRed ginseng monograph — reviewView study →}. Nothing in the clinical record can be attributed to Rg1 specifically.

Two features make the inference from isolate to plant weaker than usual. The first is route: much of the animal work injects Rg1, precisely to bypass the gut wall that an oral dose has to cross. The second is metabolism: an oral dose of ginseng delivers to the bloodstream mostly the bacterial metabolites of its saponins, not the saponins themselves ^{12,25Reference 12Hasegawa H · 2004ReviewProof of the mysterious efficacy of ginseng: metabolic activation of ginsenoside — deglycosylation by intestinal bacteria and esterification with fatty acid — reviewView study →Reference 25Odani T et al. · 1983AnimalStudies on the absorption, distribution, excretion and metabolism of ginseng saponinsView study →}. So an in-vitro concentration of Rg1 that produces eNOS phosphorylation in an endothelial monolayer is not a concentration a cup of ginseng tea creates in a person.

The one place the isolate-to-plant link is genuinely strong is the Rg1:Rb1 ratio. Reconstituting ginseng extracts at different ratios of the two purified saponins reproduced the opposite vascular behaviours of the source species ^{15Reference 15Sengupta S et al. · 2004In vitroModulating angiogenesis: the yin and the yang in ginseng — in vivo and in vitroView study →} — a rare case where isolated-molecule work explains a whole-extract observation rather than merely accompanying it.

Its Role in Plants

Rg1 is one end-product of a short, well-mapped biosynthetic route. The squalene-derived cation is cyclised by dammarenediol-II synthase; CYP716A47 hydroxylates dammarenediol-II to protopanaxadiol ^{19Reference 19Han JY et al. · 2011The Cyt P450 enzyme CYP716A47 catalyzes the formation of protopanaxadiol from dammarenediol-II during ginsenoside biosynthesis in Panax ginsengView study →}; and a second P450, CYP716A53v2, hydroxylates protopanaxadiol at C-6 to give protopanaxatriol, the aglycone of Rg1 ^{18Reference 18Han JY et al. · 2012Cytochrome P450 CYP716A53v2 catalyzes the formation of protopanaxatriol from protopanaxadiol during ginsenoside biosynthesis in Panax ginsengView study →}. Glycosyltransferases then attach the sugars. That second hydroxylation is the entire PPD/PPT divide — one enzyme decides whether a molecule ends up in Rb1’s family or Rg1’s.

The ecological function is chemical defence, and here the two saponin families behave differently enough that it is worth separating them. Tested against six fungi, both the PPT fraction (which carries Rg1) and the PPD fraction inhibited the growth of five non-pathogens, with PPT the more active of the two ^{20Reference 20Zhao X et al. · 2012In vitroFungal sensitivity to and enzymatic deglycosylation of ginsenosides — in vitroView study →}. Against Cylindrocarpon destructans, the fungus responsible for ginseng root rot, the split was starker: the PPT fraction inhibited it, while the PPD fraction significantly enhanced its growth ^{20Reference 20Zhao X et al. · 2012In vitroFungal sensitivity to and enzymatic deglycosylation of ginsenosides — in vitroView study →}. The pathogen turned out to carry extracellular glycosidases that strip sugars from the C-3 and C-20 chains of PPD-type ginsenosides — the same deglycosylation chemistry the human gut microbiota performs, repurposed as a virulence factor. Ginseng’s saponins are a defence its specialist pathogen has learned to eat.

Anatomy follows the chemistry. In Panax notoginseng, the underground organs carry both PPT and PPD saponins, but the leaf and flower carry protopanaxadiol-type saponins only — Rg1 is a root-and- rhizome molecule, and no saponin at all is detectable in the seed ^{21Reference 21Wan JB et al. · 2006Chemical characteristics for different parts of Panax notoginseng using pressurized liquid extraction and HPLC-ELSDView study →}.

Prevalence in Nature

Rg1 is a genus molecule: it occurs in Panax (Araliaceae) and essentially nowhere else in the diet. Within the genus it is the dominant protopanaxatriol saponin, and its share of the total is what distinguishes one ginseng from another. Panax ginseng is comparatively Rg1-rich; Panax quinquefolius (American ginseng) is not, carrying more Rb1, Re and Rd instead — so the Rg1:Rb1 ratio is high in Asian ginseng and low in American ^{16Reference 16Chen CF et al. · 2008ReviewComparison of the pharmacological effects of Panax ginseng and Panax quinquefolium — reviewView study →}. Panax notoginseng (Sanqi) is richer in total ginsenosides than either, roughly twice white American ginseng and five times white Asian ginseng ^{22Reference 22Sun S et al. · 2011In vitroRed notoginseng: higher ginsenoside content and stronger anticancer potential than Asian and American ginseng — in vitroView study →}, and it is the practical commercial source of Rg1.

Two processing facts matter more than they look. Korean red ginseng is regulated on a combined marker of ginsenosides Rb1, Rg1 and Rg3 of 2.5–34 mg/g — an eleven-fold permitted range, which is the honest scale of variation in commercial material ^{23Reference 23So SH et al. · 2018ReviewRed ginseng monograph — reviewView study →}. And steaming to make red ginseng lowers Rg1 along with Re, Rb1, Rc and Rd, while raising the less polar Rg2, Rh1 and Rg3 ^{23Reference 23So SH et al. · 2018ReviewRed ginseng monograph — reviewView study →}; in fresh root a large share of the polar ginsenosides also exists as malonyl esters that only convert to the familiar forms during processing ^{23Reference 23So SH et al. · 2018ReviewRed ginseng monograph — reviewView study →}. “Rg1 content” is therefore a statement about a preparation, not about a species.

Major Natural Sources

Source	Part	Rg1 status
Asian ginseng (Panax ginseng)	Root	The classic source; Rg1-rich relative to Rb1, the high-ratio species 16Reference 16Chen CF et al. · 2008ReviewComparison of the pharmacological effects of Panax ginseng and Panax quinquefolium — reviewView study →
Notoginseng (Panax notoginseng)	Root, rhizome	Highest total ginsenoside content of the three commercial ginsengs 22Reference 22Sun S et al. · 2011In vitroRed notoginseng: higher ginsenoside content and stronger anticancer potential than Asian and American ginseng — in vitroView study →; the usual commercial source of Rg1
American ginseng (Panax quinquefolius)	Root	Present but subordinate — Rb1, Re and Rd dominate; low Rg1:Rb1 ratio 16Reference 16Chen CF et al. · 2008ReviewComparison of the pharmacological effects of Panax ginseng and Panax quinquefolium — reviewView study →
Notoginseng	Leaf, flower	Protopanaxadiol saponins only — no Rg1 21Reference 21Wan JB et al. · 2006Chemical characteristics for different parts of Panax notoginseng using pressurized liquid extraction and HPLC-ELSDView study →
Notoginseng	Seed	No saponins detected 21Reference 21Wan JB et al. · 2006Chemical characteristics for different parts of Panax notoginseng using pressurized liquid extraction and HPLC-ELSDView study →

Discovery & Synthesis

Rg1’s structure was settled in 1968 by Yumiko Iida, Osamu Tanaka and Shoji Shibata at the University of Tokyo, in a Tetrahedron Letters paper titled simply “Studies on saponins of ginseng: the structure of ginsenoside-Rg1” ^{24Reference 24Iida Y et al. · 1968Studies on saponins of ginseng: the structure of ginsenoside-Rg1View study →}. It belongs to the same Japanese programme that resolved the protopanaxadiol saponins a few years later ^{23Reference 23So SH et al. · 2018ReviewRed ginseng monograph — reviewView study →} and that gave the whole family its curious naming system — R for the root, and a letter-and-subscript index assigned in order of chromatographic mobility rather than of discovery or importance. That is why Rb1 and Rg1 have adjacent-sounding names and quite different chemistry: the labels record where the spots landed on a thin-layer plate.

The pharmacokinetic half of the story followed in Japan too, in a long Chemical and Pharmaceutical Bulletin series through the early 1980s that tracked what happens to Rg1 and Rb1 in the rat digestive tract — the work that first showed the parent saponins do not survive it ^{25Reference 25Odani T et al. · 1983AnimalStudies on the absorption, distribution, excretion and metabolism of ginseng saponinsView study →}.

There is no commercially relevant total synthesis of Rg1. The molecule is a dammarane triterpene with two glycosidic attachments and defined stereochemistry at C-20, and it is cheaper to get it from Panax: commercial Rg1 is isolated from root or rhizome, typically notoginseng, by solvent extraction and chromatography. The active alternative is biotechnological rather than synthetic — the ginsenoside pathway genes have been transferred into tobacco and rice, and heterologous expression of PgDDS, CYP716A47 and CYP716A53v2 produces the protopanaxatriol aglycone in a host plant ^{18,19Reference 18Han JY et al. · 2012Cytochrome P450 CYP716A53v2 catalyzes the formation of protopanaxatriol from protopanaxadiol during ginsenoside biosynthesis in Panax ginsengView study →Reference 19Han JY et al. · 2011The Cyt P450 enzyme CYP716A47 catalyzes the formation of protopanaxadiol from dammarenediol-II during ginsenoside biosynthesis in Panax ginsengView study →}.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

Isolated Rg1 is regarded as low-toxicity — a safety evaluation of a salvianolic-acid-B + Rg1 combination in mice found no structural or biochemical toxicity in major organs, and Rg1’s poor oral absorption and heavy first-pass metabolism keep systemic exposure low, further limiting the chance of reaching toxic levels ^{14Reference 14Zhao Q et al. · 2015AnimalThe safety evaluation of salvianolic acid B and ginsenoside Rg1 combination on mice — animal modelView study →}. The most substantive safety flag is its estrogenic activity: isolated Rg1 produces estrogen-receptor-dependent effects in vitro ^{6,9Reference 6Chan RY et al. · 2002In vitroEstrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng — in vitroView study →Reference 9Gao QG et al. · 2019In vitroGinsenoside Rg1 activates ligand-independent estrogenic effects via rapid estrogen receptor signaling pathway — in vitroView study →}, and although this did not translate to an in-vivo uterotrophic response in mice ^{7Reference 7Chen WF et al. · 2012In vitroEstrogenic effects of ginsenoside Rg1 in endometrial cells in vitro were not observed in immature CD-1 mice or ovariectomised mice model — in vitro and animal modelView study →}, the theoretical concern in hormone-sensitive conditions is real. Its pro-angiogenic action is a second caution — desirable for wound healing or ischemia, but potentially unwanted where angiogenesis drives disease. No dedicated interaction studies of isolated Rg1 in humans exist; whole-ginseng cautions (e.g. around anticoagulants and stimulants) are the practical reference point, not isolate data.

Dosage

There is no established human dose of isolated ginsenoside Rg1. Efficacy figures come only from animal work — rodent neuroprotection and anti-fatigue studies typically dose in the low milligrams-per-kilogram range by injection or gavage, chosen for the experiment rather than validated for people ^{1,2,5Reference 1Zhu J et al. · 2014AnimalGinsenoside Rg1 prevents cognitive impairment and hippocampus senescence in a rat model of D-galactose-induced aging — animal modelView study →Reference 2Li F et al. · 2016AnimalGinsenoside Rg1 ameliorates hippocampal long-term potentiation and memory in an Alzheimer’s disease model — animal modelView study →Reference 5Lei C et al. · 2023AnimalGinsenoside Rg1 can reverse fatigue behavior in CFS rats by regulating EGFR and affecting taurine and mannose 6-phosphate metabolism — animal modelView study →}. Because oral Rg1 is poorly absorbed and largely converted to Rh1/F1 by gut bacteria before it acts, an oral milligram figure does not map cleanly onto delivered exposure ^{8,12Reference 8Xu QF et al. · 2003AnimalPharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats — animal modelView study →Reference 12Hasegawa H · 2004ReviewProof of the mysterious efficacy of ginseng: metabolic activation of ginsenoside — deglycosylation by intestinal bacteria and esterification with fatty acid — reviewView study →}. In practice, human intake of Rg1 happens through standardized whole-ginseng extracts, where Rg1 is one of many saponins and its individual contribution is unknown.

These are doses studied in research and are not a personal recommendation.

References

1. Zhu J, Mu X, Zeng J, et al. (2014). Ginsenoside Rg1 prevents cognitive impairment and hippocampus senescence in a rat model of D-galactose-induced aging — animal model. PLoS One, 9(6), e101291. https://pubmed.ncbi.nlm.nih.gov/24979747/
2. Li F, Wu X, Li J, Niu Q. (2016). Ginsenoside Rg1 ameliorates hippocampal long-term potentiation and memory in an Alzheimer’s disease model — animal model. Molecular Medicine Reports, 13(6), 4904–4910. https://pubmed.ncbi.nlm.nih.gov/27082952/
3. Leung KW, Cheng YK, Mak NK, Chan KK, et al. (2006). Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells — in vitro. FEBS Letters, 580(13), 3211–3216. https://pubmed.ncbi.nlm.nih.gov/16696977/
4. Leung KW, Pon YL, Wong RN, et al. (2006). Ginsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related PI3-kinase/Akt and β-catenin/T-cell factor-dependent pathway in human endothelial cells — in vitro. The Journal of Biological Chemistry, 281(47), 36280–36288. https://pubmed.ncbi.nlm.nih.gov/17008323/
5. Lei C, Chen J, Huang Z, et al. (2023). Ginsenoside Rg1 can reverse fatigue behavior in CFS rats by regulating EGFR and affecting taurine and mannose 6-phosphate metabolism — animal model. Frontiers in Pharmacology, 14, 1163638. https://pubmed.ncbi.nlm.nih.gov/37101547/
6. Chan RY, Chen WF, Dong A, et al. (2002). Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng — in vitro. The Journal of Clinical Endocrinology and Metabolism, 87(8), 3691–3695. https://pubmed.ncbi.nlm.nih.gov/12161497/
7. Chen WF, Gao QG, Dai ZJ, et al. (2012). Estrogenic effects of ginsenoside Rg1 in endometrial cells in vitro were not observed in immature CD-1 mice or ovariectomised mice model — in vitro and animal model. Menopause, 19(3), 355–364. https://pubmed.ncbi.nlm.nih.gov/22549169/
8. Xu QF, Fang XL, Chen DF. (2003). Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats — animal model. Journal of Ethnopharmacology, 84(2–3), 187–192. https://pubmed.ncbi.nlm.nih.gov/12648814/
9. Gao QG, Zhou LP, Lee VH, et al. (2019). Ginsenoside Rg1 activates ligand-independent estrogenic effects via rapid estrogen receptor signaling pathway — in vitro. Journal of Ginseng Research, 43(4), 527–538. https://pubmed.ncbi.nlm.nih.gov/31695561/
10. Liang HY, Zhang PP, Zhang XL, et al. (2021). Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease — systematic review of animal studies. Aging, 13(5), 7549–7569. https://pubmed.ncbi.nlm.nih.gov/33686024/
11. Feng L, Wang L, Hu C, Jiang X. (2010). Pharmacokinetics, tissue distribution, metabolism, and excretion of ginsenoside Rg1 in rats — animal model. Archives of Pharmacal Research, 33(12), 1975–1984. https://pubmed.ncbi.nlm.nih.gov/21191763/
12. Hasegawa H. (2004). Proof of the mysterious efficacy of ginseng: metabolic activation of ginsenoside — deglycosylation by intestinal bacteria and esterification with fatty acid — review. Journal of Pharmacological Sciences, 95(2), 153–157. https://pubmed.ncbi.nlm.nih.gov/15215638/
13. Sun Y, Yang Y, Liu S, et al. (2022). New therapeutic approaches to and mechanisms of ginsenoside Rg1 against neurological diseases — review. Cells, 11(16), 2529. https://pubmed.ncbi.nlm.nih.gov/36010610/
14. Zhao Q, Yang M, Deng Y, et al. (2015). The safety evaluation of salvianolic acid B and ginsenoside Rg1 combination on mice — animal model. International Journal of Molecular Sciences, 16(12), 29345–29356. https://pubmed.ncbi.nlm.nih.gov/26690140/
15. Sengupta S, Toh SA, Sellers LA, et al. (2004). Modulating angiogenesis: the yin and the yang in ginseng — in vivo and in vitro. Circulation. https://pubmed.ncbi.nlm.nih.gov/15337705/
16. Chen CF, Chiou WF, Zhang JT (2008). Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium — review. Acta Pharmacologica Sinica. https://pubmed.ncbi.nlm.nih.gov/18718179/
17. Wang Q, Sun LH, Jia W, et al. (2010). Comparison of ginsenosides Rg1 and Rb1 for their effects on improving scopolamine-induced learning and memory impairment in mice — animal model. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/20564503/
18. Han JY, Hwang HS, Choi SW, et al. (2012). Cytochrome P450 CYP716A53v2 catalyzes the formation of protopanaxatriol from protopanaxadiol during ginsenoside biosynthesis in Panax ginseng. Plant and Cell Physiology. https://pubmed.ncbi.nlm.nih.gov/22875608/
19. Han JY, Kim HJ, Kwon YS, et al. (2011). The Cyt P450 enzyme CYP716A47 catalyzes the formation of protopanaxadiol from dammarenediol-II during ginsenoside biosynthesis in Panax ginseng. Plant and Cell Physiology. https://pubmed.ncbi.nlm.nih.gov/22039120/
20. Zhao X, Gao J, Song C, et al. (2012). Fungal sensitivity to and enzymatic deglycosylation of ginsenosides — in vitro. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/22449289/
21. Wan JB, Yang FQ, Li SP, et al. (2006). Chemical characteristics for different parts of Panax notoginseng using pressurized liquid extraction and HPLC-ELSD. Journal of Pharmaceutical and Biomedical Analysis. https://pubmed.ncbi.nlm.nih.gov/16522361/
22. Sun S, Qi LW, Du GJ, et al. (2011). Red notoginseng: higher ginsenoside content and stronger anticancer potential than Asian and American ginseng — in vitro. Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/21344064/
23. So SH, Lee JW, Kim YS, et al. (2018). Red ginseng monograph — review. Journal of Ginseng Research. https://pubmed.ncbi.nlm.nih.gov/30337816/
24. Iida Y, Tanaka O, Shibata S (1968). Studies on saponins of ginseng: the structure of ginsenoside-Rg1. Tetrahedron Letters. https://doi.org/10.1016/s0040-4039(00)89801-9
25. Odani T, Tanizawa H, Takino Y (1983). Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. IV. Decomposition of ginsenoside-Rg1 and -Rb1 in the digestive tract of rats — animal model. Chemical and Pharmaceutical Bulletin. https://doi.org/10.1248/cpb.31.3691

View all 25 references▾